<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 4pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D)
OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">THE SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">Date of report (Date of earliest event reported)</TD>
    <TD STYLE="width: 50%; border-bottom: black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">February 8, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1.5pt solid; font-size: 18pt; font-weight: bold; text-align: center">NANOVIRICIDES, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 33%; vertical-align: top; font-weight: bold; text-align: center">Nevada</TD>
    <TD STYLE="width: 34%; vertical-align: top; font-weight: bold; text-align: center">000-1379006</TD>
    <TD STYLE="width: 33%; vertical-align: bottom; font-weight: bold; text-align: center">76-0674577</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or Other Jurisdiction of Incorporation)</TD>
    <TD STYLE="text-align: center">(Commission File Number)</TD>
    <TD STYLE="text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>135 Wood Street, Suite 205</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>West Haven, Connecticut</B></P></TD>
    <TD STYLE="font-weight: bold; text-align: center">06516</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">(Address of Principal Executive Offices)</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt; font-weight: bold; text-align: center">(203) 937-6137</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">(Registrant's Telephone Number, Including Area Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Copies to:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Peter Campitiello, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Tarter Krinsky &amp; Drogin LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">1350 Broadway</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">New York, New York 10018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Tel: 212-216-8085</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Fax: 212-216-8001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-family: Wingdings">&uml;</TD>
    <TD>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Wingdings">&uml;</TD>
    <TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Wingdings">&uml;</TD>
    <TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Wingdings">&uml;</TD>
    <TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 8.01 Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 8, 2012, pursuant
to that certain Securities Purchase Agreement (&ldquo;Agreement&rdquo;), dated November 1, 2011, by and between the Registrant
and Seaside 88, LP (&ldquo;Seaside&rdquo;), Seaside purchased 250,000 shares of the Registrant&rsquo;s Series B Convertible Preferred
Stock (the &ldquo;Series B Preferred Stock&rdquo;) at the purchase price of $10.00 per share (the &ldquo;Purchase Price&rdquo;)
for an aggregate purchase price of $2,500,000. 40,000 shares of Series B Preferred Stock automatically converted into shares of
the Registrant&rsquo;s common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;) on February 8, 2012 and 40,000
shares (or such lesser number that remains unconverted) shall convert every fourteen (14) days thereafter. Each share of Series
B Preferred Stock converts into shares of Common Stock at a conversion factor equal to the Purchase Price divided by the lower
of (i) the daily volume weighted average of actual trading prices of the Common Stock on the trading market (the &ldquo;VWAP&rdquo;)
for the ten (10) consecutive trading days immediately prior to a conversion date multiplied by 0.85 or (ii) the VWAP for the trading
day immediately prior to a conversion date multiplied by 0.88.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Series B Preferred
Stock accrues dividends at the rate per annum of 10% per share. The dividend can be paid in either cash or in shares of Common
Stock at a 15% discount to the ten (10) trading day VWAP immediately preceding the dividend date. Dividends are payable at each
conversion date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In no event will a conversion
of the Series B Preferred Stock into Common Stock occur if the VWAP of the Common Stock during the 20-day trading period immediately
preceding a conversion date does not exceed a floor of $0.20 or the registration statement with respect to the shares of Common
Stock being issued upon conversion is not in effect. If a conversion fails to occur because the registration statement is not in
effect, Seaside has available to it certain redemption rights as described in the Certificate of Designation. If a conversion fails
to occur because the floor has not been met, the shares not converted on such conversion date are added to the shares to be converted
on the following conversion date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The conversion price per
share for the closing on February 8, 2012 was $0.55777, and the Registrant raised gross proceeds from the offering of $2,500,000,
before estimated offering expenses of approximately $180,000, which includes placement agent and attorneys&rsquo; fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The offering is made pursuant
to the Registrant&rsquo;s shelf registration statement on Form S-3 (File No. 333-165221), which was declared effective by the Securities
and Exchange Commission on April 29, 2010.&nbsp;&nbsp;The Registrant, pursuant to Rule 424(b) under the Securities Act of 1933,
has filed with the Securities and Exchange Commission a prospectus supplement relating to the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the
offering, pursuant to that Placement Agency Agreement entered into by and between Midtown Partners &amp; Co., LLC (&ldquo;Midtown&rdquo;)
and the Registrant, as amended by an Underwriter Agent Agreement Amendment No. 1 entered into by the parties on March 28, 2011
(as amended, the &ldquo;Placement Agency Agreement&rdquo;), the Registrant will pay Midtown a cash fee representing 6% of the gross
purchase price paid by Seaside for the Series B Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 9, 2012, the
Registrant issued a press release announcing the closing. A copy of the press release is attached hereto as Exhibit 99.1, and is
incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The foregoing is only a
summary of the material terms of the Agreement and the Placement Agency Agreement. The foregoing descriptions of the Agreement
and the Placement Agency Agreement are qualified in their entirety by reference to the Agreement, filed as Exhibit 10.1 to the
Registrant&rsquo;s Current Report on Form 8-K filed on November 1, 2011 and the original Placement Agent Agreement filed as Exhibit
1.1 to the Registrant&rsquo;s Current Report on Form 8-K filed on May 12, 2010 and the amendment thereto filed as Exhibit 1.2 to
the Registrant&rsquo;s Current Report on Form 8-K filed on April 19, 2011, and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Current Report on
Form 8-K contains forward-looking statements that involve risk and uncertainties, such as statements related to the anticipated
subsequent conversions of common stock in connection with the offering. The risks and uncertainties involved include the Registrant&rsquo;s
ability to satisfy certain conditions to closing on a timely basis or at all, the substantial dilution to current stockholders
as a result of the purchase price discount offered to Seaside, and the market overhang of shares available for sale that may develop
as a result of the subsequent resale by Seaside of the shares of Common Stock it may issue upon conversion of the Series B Preferred
Stock under the Agreement, as well as other risks detailed from time to time in the Registrant&rsquo;s periodic filings with the
Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 84px; font-weight: bold">Item 9.01&nbsp;</TD>
    <TD STYLE="font-weight: bold">Financial Statements and Exhibits.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">(d)</TD>
    <TD STYLE="font-weight: bold">Exhibits.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 11%; vertical-align: top; border-bottom: black 1.5pt solid; font-weight: bold">Exhibit <BR>
Number</TD>
    <TD STYLE="width: 1%; vertical-align: top; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 88%; vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold; text-align: center">Description</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>1.1</TD>
    <TD>&nbsp;</TD>
    <TD>Placement Agency Agreement, dated March 3, 2010, by and between NanoViricides, Inc. and Midtown Partners &amp; Co., LLC.(1)</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>1.2</TD>
    <TD>&nbsp;</TD>
    <TD>Underwriter Agent Agreement Amendment No. 1 dated March 28, 2011(2)</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>10.1</TD>
    <TD>&nbsp;</TD>
    <TD>Securities Purchase Agreement dated November 1, 2011 by and between NanoViricides, Inc. and Seaside 88, LP. (3)</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>99.1<FONT STYLE="letter-spacing: 9pt">&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Press Release dated February 9, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 5%">(1)</TD>
    <TD STYLE="width: 88%">Incorporated by reference from the Registrant&rsquo;s Form 8-K filed on May 12, 2010.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 5%">(2)</TD>
    <TD STYLE="width: 88%">Incorporated by reference from the Registrant&rsquo;s Form 8-K filed on April 19, 2011.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 5%">(3)</TD>
    <TD STYLE="width: 88%">Incorporated by reference from the Registrant&rsquo;s Form 8-K filed on November 3, 2011.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF
1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">NANOVIRICIDES, INC.</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 50%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 3%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 32%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">Date: February 9, 2012</TD>
    <TD STYLE="vertical-align: top">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top">&nbsp;/s/ Anil Diwan</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Dr. Anil Diwan, Ph.D.</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">President, Chairman</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exhibit Index</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 11%; vertical-align: top; border-bottom: black 1.5pt solid; font-weight: bold">Exhibit <BR>
Number</TD>
    <TD STYLE="width: 1%; vertical-align: top; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 88%; vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold; text-align: center">Description</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>1.1</TD>
    <TD>&nbsp;</TD>
    <TD>Placement Agency Agreement, dated March 3, 2010, by and between NanoViricides, Inc. and Midtown Partners &amp; Co., LLC.(1)</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>1.2</TD>
    <TD>&nbsp;</TD>
    <TD>Underwriter Agent Agreement Amendment No. 1 dated March 28, 2011(2)</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>10.1</TD>
    <TD>&nbsp;</TD>
    <TD>Securities Purchase Agreement dated November 1, 2011 by and between NanoViricides, Inc. and Seaside 88, LP. (3)</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>99.1<FONT STYLE="letter-spacing: 9pt">&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Press Release dated February 9, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 5%">(1)</TD>
    <TD STYLE="width: 88%">Incorporated by reference from the Registrant&rsquo;s Form 8-K filed on May 12, 2010.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 5%">(2)</TD>
    <TD STYLE="width: 88%">Incorporated by reference from the Registrant&rsquo;s Form 8-K filed on April 19, 2011.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 5%">(3)</TD>
    <TD STYLE="width: 88%">Incorporated by reference from the Registrant&rsquo;s Form 8-K filed on November 3, 2011.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v301853_8-k.htm", "description": "CURRENT REPORT", "secsgml_size_bytes": 25466}]
{"company-data": {"conformed-name": "NANOVIRICIDES, INC.", "cik": "0001379006", "assigned-sic": "8731", "irs-number": "760674577", "state-of-incorporation": "NV", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-52318", "film-number": "12586155"}, "business-address": {"street1": "135 WOOD STREET", "street2": "SUITE 205", "city": "WEST HAVEN", "state": "CT", "zip": "06516", "phone": "(203) 937-6137"}, "mail-address": {"street1": "135 WOOD STREET", "street2": "SUITE 205", "city": "WEST HAVEN", "state": "CT", "zip": "06516"}}
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported)
February 8, 2012
NANOVIRICIDES, INC.
(Exact Name of Registrant as Specified in Its Charter)
Nevada
000-1379006
76-0674577
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
135 Wood Street, Suite 205
West Haven, Connecticut
06516
(Address of Principal Executive Offices)
(Zip Code)
(203) 937-6137
(Registrant's Telephone Number, Including Area Code)
Copies to:
Peter Campitiello, Esq.
Tarter Krinsky & Drogin LLP
1350 Broadway
New York, New York 10018
Tel: 212-216-8085
Fax: 212-216-8001
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On February 8, 2012, pursuant
to that certain Securities Purchase Agreement ("Agreement"), dated November 1, 2011, by and between the Registrant
and Seaside 88, LP ("Seaside"), Seaside purchased 250,000 shares of the Registrant's Series B Convertible Preferred
Stock (the "Series B Preferred Stock") at the purchase price of $10.00 per share (the "Purchase Price")
for an aggregate purchase price of $2,500,000. 40,000 shares of Series B Preferred Stock automatically converted into shares of
the Registrant's common stock, par value $0.001 per share (the "Common Stock") on February 8, 2012 and 40,000
shares (or such lesser number that remains unconverted) shall convert every fourteen (14) days thereafter. Each share of Series
B Preferred Stock converts into shares of Common Stock at a conversion factor equal to the Purchase Price divided by the lower
of (i) the daily volume weighted average of actual trading prices of the Common Stock on the trading market (the "VWAP")
for the ten (10) consecutive trading days immediately prior to a conversion date multiplied by 0.85 or (ii) the VWAP for the trading
day immediately prior to a conversion date multiplied by 0.88.
The Series B Preferred
Stock accrues dividends at the rate per annum of 10% per share. The dividend can be paid in either cash or in shares of Common
Stock at a 15% discount to the ten (10) trading day VWAP immediately preceding the dividend date. Dividends are payable at each
conversion date.
In no event will a conversion
of the Series B Preferred Stock into Common Stock occur if the VWAP of the Common Stock during the 20-day trading period immediately
preceding a conversion date does not exceed a floor of $0.20 or the registration statement with respect to the shares of Common
Stock being issued upon conversion is not in effect. If a conversion fails to occur because the registration statement is not in
effect, Seaside has available to it certain redemption rights as described in the Certificate of Designation. If a conversion fails
to occur because the floor has not been met, the shares not converted on such conversion date are added to the shares to be converted
on the following conversion date.
The conversion price per
share for the closing on February 8, 2012 was $0.55777, and the Registrant raised gross proceeds from the offering of $2,500,000,
before estimated offering expenses of approximately $180,000, which includes placement agent and attorneys' fees.
The offering is made pursuant
to the Registrant's shelf registration statement on Form S-3 (File No. 333-165221), which was declared effective by the Securities
and Exchange Commission on April 29, 2010.  The Registrant, pursuant to Rule 424(b) under the Securities Act of 1933,
has filed with the Securities and Exchange Commission a prospectus supplement relating to the offering.
In connection with the
offering, pursuant to that Placement Agency Agreement entered into by and between Midtown Partners & Co., LLC ("Midtown")
and the Registrant, as amended by an Underwriter Agent Agreement Amendment No. 1 entered into by the parties on March 28, 2011
(as amended, the "Placement Agency Agreement"), the Registrant will pay Midtown a cash fee representing 6% of the gross
purchase price paid by Seaside for the Series B Preferred Stock.
On February 9, 2012, the
Registrant issued a press release announcing the closing. A copy of the press release is attached hereto as Exhibit 99.1, and is
incorporated herein by reference.
The foregoing is only a
summary of the material terms of the Agreement and the Placement Agency Agreement. The foregoing descriptions of the Agreement
and the Placement Agency Agreement are qualified in their entirety by reference to the Agreement, filed as Exhibit 10.1 to the
Registrant's Current Report on Form 8-K filed on November 1, 2011 and the original Placement Agent Agreement filed as Exhibit
1.1 to the Registrant's Current Report on Form 8-K filed on May 12, 2010 and the amendment thereto filed as Exhibit 1.2 to
the Registrant's Current Report on Form 8-K filed on April 19, 2011, and incorporated herein by reference.
This Current Report on
Form 8-K contains forward-looking statements that involve risk and uncertainties, such as statements related to the anticipated
subsequent conversions of common stock in connection with the offering. The risks and uncertainties involved include the Registrant's
ability to satisfy certain conditions to closing on a timely basis or at all, the substantial dilution to current stockholders
as a result of the purchase price discount offered to Seaside, and the market overhang of shares available for sale that may develop
as a result of the subsequent resale by Seaside of the shares of Common Stock it may issue upon conversion of the Series B Preferred
Stock under the Agreement, as well as other risks detailed from time to time in the Registrant's periodic filings with the
Securities and Exchange Commission.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
Number
Description
1.1
Placement Agency Agreement, dated March 3, 2010, by and between NanoViricides, Inc. and Midtown Partners & Co., LLC.(1)
1.2
Underwriter Agent Agreement Amendment No. 1 dated March 28, 2011(2)
10.1
Securities Purchase Agreement dated November 1, 2011 by and between NanoViricides, Inc. and Seaside 88, LP. (3)
99.1
Press Release dated February 9, 2012
(1)
Incorporated by reference from the Registrant's Form 8-K filed on May 12, 2010.
(2)
Incorporated by reference from the Registrant's Form 8-K filed on April 19, 2011.
(3)
Incorporated by reference from the Registrant's Form 8-K filed on November 3, 2011.
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF
1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.
NANOVIRICIDES, INC.
Date: February 9, 2012
By:
/s/ Anil Diwan
Dr. Anil Diwan, Ph.D.
President, Chairman
Exhibit Index
Exhibit
Number
Description
1.1
Placement Agency Agreement, dated March 3, 2010, by and between NanoViricides, Inc. and Midtown Partners & Co., LLC.(1)
1.2
Underwriter Agent Agreement Amendment No. 1 dated March 28, 2011(2)
10.1
Securities Purchase Agreement dated November 1, 2011 by and between NanoViricides, Inc. and Seaside 88, LP. (3)
99.1
Press Release dated February 9, 2012
(1)
Incorporated by reference from the Registrant's Form 8-K filed on May 12, 2010.
(2)
Incorporated by reference from the Registrant's Form 8-K filed on April 19, 2011.
(3)
Incorporated by reference from the Registrant's Form 8-K filed on November 3, 2011.